Research programme: vitiligo therapy - BTG/King's College London
Alternative Names: Cyclohexylpiperine - BTG; Piperine - BTG; Piperine analogues - BTG; Tetrahydropiperine - BTG; Vitiligo therapy research programme - BTG/King's College LondonLatest Information Update: 21 Aug 2019
At a glance
- Originator BTG; Kings College London
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vitiligo
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 May 2007 No development reported - Preclinical for Vitiligo in United Kingdom (unspecified route)
- 05 Mar 2004 Piperine-based compounds are available for licensing (http://www.btgplc.com)